Effect of Coffeeberry on Mood and Cognitive Performance

NCT ID: NCT04975802

Last Updated: 2022-03-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-05

Study Completion Date

2022-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this randomised, double-blind, placebo-controlled, cross-over study is to assess the short-term cognitive effects of two beverages containing 100 and 300 mg coffeeberry extract (obtained from the fruit of the coffee plant (Coffea arabica) compared to a placebo beverage. The trial will utilise the COMPASS cognitive assessment system and cognitive demand battery (CDB) and mood visual analogue scales (VAS) with assessments taking place at baseline, 60- and 120-minutes post treatment, on four separate testing days separated by 7 days. A treatment containing 75 mg caffeine will be used as a positive control to document participants' responsiveness to an established psychostimulant.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mental Fatigue Alertness Mood Cognition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0 mg coffeeberry beverage

Appearance-matched to the other products

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

10 oz (296 ml) cherry flavored still beverage

100 mg coffeeberry beverage

Appearance-matched to the other products

Group Type EXPERIMENTAL

Coffeeberry

Intervention Type DIETARY_SUPPLEMENT

10 oz (296 ml) cherry flavored still beverage

300 mg coffeeberry beverage

Appearance-matched to the other products

Group Type EXPERIMENTAL

Coffeeberry

Intervention Type DIETARY_SUPPLEMENT

10 oz (296 ml) cherry flavored still beverage

75 mg caffeine beverage

Appearance-matched to the other products

Group Type ACTIVE_COMPARATOR

Caffeine

Intervention Type DIETARY_SUPPLEMENT

10 oz (296 ml) cherry flavored still beverage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

10 oz (296 ml) cherry flavored still beverage

Intervention Type OTHER

Coffeeberry

10 oz (296 ml) cherry flavored still beverage

Intervention Type DIETARY_SUPPLEMENT

Caffeine

10 oz (296 ml) cherry flavored still beverage

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants are aged 18-49 years, inclusive
* Participants self-report that they are in good health
* Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial
* Willing to abstain from consumption of caffeine within 12 h of testing
* Willing to abstain from alcohol consumption and avoid vigorous physical activity for 24 h prior to all test visits
* Willing to refrain from 'over the counter' medications (e.g. pain medication) and stimulant medication for 12 hours, seasonal allergy/hay fever nasal antihistamine medications for 24 hours and oral antihistamines for 48 hours prior to all test visits
* Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study Investigator.

* Current use of prescription medication, except for contraceptives
* Report hypersensitivity to caffeine
* Major trauma or major surgical event within 6 months of screening
* Extreme dietary habits, as judged by the Investigator (high fat, very high protein diets, intermittent fasting, etc.)
* Exposure to coffeeberry within 30 d prior to screening
* History of cancer in the prior two years, except for non-melanoma skin cancer
* Have a visual impairment that cannot be corrected with glasses or contact lenses
* Food allergies/intolerances/sensitivities to any ingredients in the study products (including coffee or related foods/beverages/products)
* Self-report excessive leisure time physical activity (\> 7 strenuous bouts per week)
* Have a current or chronic gastrointestinal, sleep, or psychiatric disorders
* Work night shifts or follow a variable work pattern that results in irregular sleep pattern
* Are pregnant, trying to get pregnant or lactating
* Smoke tobacco, vape nicotine or use nicotine replacement products
* Use illegal/recreational drugs
* Unable to demonstrate adequate minimal performance on lab, computer-based cognitive tasks
* Have participated in another clinical trial within past 30 days and/or participation in another PepsiCo trial in the past 6 months
* Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg)
* Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2
* Have learning and/or behavioural disorders such as dyslexia or ADHD
* Excessive caffeine intake (\>500 mg per day)
* Have taken dietary supplements e.g. Vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4 week supplement washout prior to participating and for the duration of the study on the proviso that the supplements they are taking are out of choice and not medically prescribed or advised)
* Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)
* Has been diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months
* Have been diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months
* Suffers from frequent migraines that require medication (more than or equal to 1 per month)
* Any known active infections
* Does not have a bank account (required for payment)
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PepsiCo Global R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippa Jackson, PhD

Role: PRINCIPAL_INVESTIGATOR

Northumbria University Newcastle, UK

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brain, Performance and Nutrition Research Centre Northumbria University

Newcastle upon Tyne, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PEP-2005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.